Payment overview · 2025
General Payments
$798.05
31 reported records · 11 companies
Healthcare provider profile · identity verified
Cheryl C Bazzle, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTSVILLE, AL · NPI 1942419643
Verified facts
What the public records show
CMS Open Payments records show Cheryl C Bazzle, M.D. received $798.05 in general payments during 2025 across 31 reported records.
Teva Pharmaceuticals USA, Inc. accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Rexulti.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 759 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Gemtesa by this doctor in 2024.
Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO as an associated drug or biological on 28 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Austedo by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $198.59 | 24.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $134.44 | 16.9% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $109.66 | 13.7% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $83.63 | 10.5% | 4 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $57.03 | 7.2% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $54.20 | 6.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.74 | 6.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.55 | 5.1% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.07 | 3.5% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $23.54 | 3.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.60 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $688.56 | 30 |
| Education | $109.49 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $134.44 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $124.18 | 6 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $109.66 | 5 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $89.10 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.96 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $57.03 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $54.20 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $49.74 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $28.07 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $18.60 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 243 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 32 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
759 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
131 | 17 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
88 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
243 | suppressed by CMS |
| Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference |
2025 | AUSTEDO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 15 recipient NPIs · example record 1247249192 |
Austedo · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2481 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1944 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1853 | 122 |
| Sertraline Hcl | Sertraline Hcl | 1620 | 76 |
| Trazodone Hcl | Trazodone Hcl | 1536 | 81 |
| Potassium Chloride | Potassium Chloride | 1453 | 78 |
| Furosemide | Furosemide | 1430 | 74 |
| Amlodipine Besylate | Amlodipine Besylate | 1272 | 89 |
| Eliquis | Apixaban | 1171 | 53 |
| Donepezil Hcl | Donepezil Hcl | 1122 | 50 |
| Lisinopril | Lisinopril | 1039 | 58 |
| Famotidine | Famotidine | 927 | 50 |
| Memantine Hcl | Memantine Hcl | 916 | 31 |
| Montelukast Sodium | Montelukast Sodium | 869 | 44 |
| Buspirone Hcl | Buspirone Hcl | 868 | 34 |
| Metoprolol Succinate | Metoprolol Succinate | 868 | 49 |
| Tamsulosin Hcl | Tamsulosin Hcl | 863 | 45 |
| Mirtazapine | Mirtazapine | 850 | 40 |
| Omeprazole | Omeprazole | 848 | 53 |
| Quetiapine Fumarate | Quetiapine Fumarate | 802 | 36 |
| Jardiance | Empagliflozin | 759 | 31 |
| Losartan Potassium | Losartan Potassium | 679 | 47 |
| Carvedilol | Carvedilol | 641 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 609 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 555 | 36 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 520 | 39 |
| Gabapentin | Gabapentin | 514 | 70 |
| Hydralazine Hcl | Hydralazine Hcl | 512 | 39 |
| Risperidone | Risperidone | 509 | 18 |
| Levetiracetam | Levetiracetam | 501 | 21 |
| Clopidogrel | Clopidogrel Bisulfate | 483 | 26 |
| Baclofen | Baclofen | 431 | 18 |
| Metformin Hcl | Metformin Hcl | 429 | 39 |
| Divalproex Sodium Er | Divalproex Sodium | 426 | 11 |
| Divalproex Sodium | Divalproex Sodium | 400 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 382 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 381 | 17 |
| Torsemide | Torsemide | 369 | 20 |
| Oxcarbazepine | Oxcarbazepine | 340 | suppressed |
| Xarelto | Rivaroxaban | 340 | suppressed |
| Olanzapine | Olanzapine | 334 | 12 |
| Spironolactone | Spironolactone | 324 | 20 |
| Movantik | Naloxegol Oxalate | 319 | 14 |
| Methocarbamol | Methocarbamol | 313 | 34 |
| Citalopram Hbr | Citalopram Hydrobromide | 296 | 24 |
| Sucralfate | Sucralfate | 284 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 282 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 280 | 15 |
| Fenofibrate | Fenofibrate | 277 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 270 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 262 | 57 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 259 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 244 | 11 |
| Gemtesa | Vibegron | 243 | suppressed |
| Myrbetriq | Mirabegron | 220 | suppressed |
| Atenolol | Atenolol | 209 | suppressed |
| Prednisone | Prednisone | 208 | 27 |
| Lorazepam | Lorazepam | 200 | 40 |
| Paroxetine Hcl | Paroxetine Hcl | 195 | suppressed |
| Ezetimibe | Ezetimibe | 194 | 14 |
| Alendronate Sodium | Alendronate Sodium | 193 | 16 |
| Metoclopramide Hcl | Metoclopramide Hcl | 186 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 180 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 174 | suppressed |
| Topiramate | Topiramate | 174 | 11 |
| Aripiprazole | Aripiprazole | 157 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 154 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 144 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 144 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 139 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 138 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 137 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 132 | 27 |
| Trulicity | Dulaglutide | 131 | 17 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 127 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 124 | 44 |
| Doxepin Hcl | Doxepin Hcl | 120 | suppressed |
| Simvastatin | Simvastatin | 120 | 23 |
| Ramelteon | Ramelteon | 118 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 112 | suppressed |
| Entresto | Sacubitril/Valsartan | 110 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 109 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 109 | suppressed |
| Lamotrigine | Lamotrigine | 108 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 108 | suppressed |
| Allopurinol | Allopurinol | 106 | 16 |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 106 | suppressed |
| Enulose | Lactulose | 103 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 99 | 12 |
| Alprazolam | Alprazolam | 98 | 15 |
| Nystop | Nystatin | 96 | 38 |
| Januvia | Sitagliptin Phosphate | 95 | suppressed |
| Digoxin | Digoxin | 94 | suppressed |
| Clonazepam | Clonazepam | 93 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 93 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 39 |
| Benazepril Hcl | Benazepril Hcl | 91 | suppressed |
| Valsartan | Valsartan | 91 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 89 | suppressed |
| Finasteride | Finasteride | 88 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 88 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 88 | suppressed |
| Tradjenta | Linagliptin | 87 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 84 | suppressed |
| Carbamazepine Er | Carbamazepine | 82 | suppressed |
| Pregabalin | Pregabalin | 82 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 82 | suppressed |
| Nifedipine Er | Nifedipine | 81 | suppressed |
| Glipizide | Glipizide | 78 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 73 | 18 |
| Fluconazole | Fluconazole | 72 | 44 |
| Linzess | Linaclotide | 71 | 14 |
| Cephalexin | Cephalexin | 69 | 14 |
| Rivastigmine | Rivastigmine Tartrate | 69 | suppressed |
| Hydrocortisone | Hydrocortisone | 68 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 68 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 67 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 67 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 12 |
| Primidone | Primidone | 65 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 64 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 63 | suppressed |
| Nystatin | Nystatin | 63 | 25 |
| Carbamazepine | Carbamazepine | 62 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 62 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 60 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 11 |
| Naltrexone Hcl | Naltrexone Hcl | 59 | suppressed |
| Ranolazine Er | Ranolazine | 59 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 13 |
| Mounjaro | Tirzepatide | 58 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 58 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 57 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 57 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 56 | suppressed |
| Ramipril | Ramipril | 56 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 55 | 12 |
| Glipizide Er | Glipizide | 55 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 55 | 22 |
| Lithium Carbonate | Lithium Carbonate | 54 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 54 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 53 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 53 | suppressed |
| Haloperidol | Haloperidol | 53 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 51 | suppressed |
| Bumetanide | Bumetanide | 50 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 50 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 50 | suppressed |
| Lacosamide | Lacosamide | 49 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 49 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 48 | 18 |
| Meclizine Hcl | Meclizine Hcl | 48 | 12 |
| Premarin | Estrogens, Conjugated | 48 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | suppressed |
| Ketoconazole | Ketoconazole | 45 | 31 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 32 |
| Bupropion Xl | Bupropion Hcl | 43 | 16 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 43 | 17 |
| Tresiba | Insulin Degludec | 43 | suppressed |
| Lactulose | Lactulose | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 36 |
| Ozempic | Semaglutide | 41 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 41 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 19 |
| Latanoprost | Latanoprost | 40 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 38 | 30 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 27 |
| Ertapenem | Ertapenem Sodium | 38 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Novolog | Insulin Aspart | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | 11 |
| Methylprednisolone | Methylprednisolone | 36 | 27 |
| Metolazone | Metolazone | 36 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Rexulti | Brexpiprazole | 32 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 27 |
| Lidocaine Hcl | Lidocaine Hcl | 31 | 26 |
| Lubiprostone | Lubiprostone | 31 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Humulin R | Insulin Regular, Human | 30 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 30 | 12 |
| Temazepam | Temazepam | 30 | suppressed |
| Azathioprine | Azathioprine | 29 | suppressed |
| Humalog | Insulin Lispro | 28 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Meloxicam | Meloxicam | 28 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 28 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 28 | suppressed |
| Clozapine | Clozapine | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 26 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 26 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 26 | 12 |
| Amoxicillin | Amoxicillin | 25 | 15 |
| Fentanyl | Fentanyl | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 18 |
| Tolterodine Tartrate | Tolterodine Tartrate | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Admelog | Insulin Lispro | 23 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 23 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 23 |
| Austedo | Deutetrabenazine | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 22 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 21 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 21 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 20 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 19 | 16 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Briviact | Brivaracetam | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 17 | 15 |
| Mupirocin | Mupirocin | 17 | 13 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Risperidone Odt | Risperidone | 16 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ubrelvy | Ubrogepant | 15 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Clonidine | Clonidine | 14 | suppressed |
| Insulin Aspart | Insulin Aspart | 14 | suppressed |
| Mirabegron Er | Mirabegron | 14 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 14 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Rivastigmine | Rivastigmine | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Valproic Acid | Valproic Acid | 14 | suppressed |
| Budesonide | Budesonide | 13 | suppressed |
| Dexamethasone | Dexamethasone | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 12 | suppressed |
| Levemir | Insulin Detemir | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | 11 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Repatha Sureclick | Evolocumab | 12 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 12 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 11 | suppressed |
| Gemfibrozil | Gemfibrozil | 11 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 11 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $798.05 · 31 records | Teva Pharmaceuticals USA, Inc. | AUSTEDO XR, CAPLYTA, FANAPT, GEMTESA, INGREZZA, KISUNLA, Kerendia, OTEZLA, REPATHA, REXULTI, The Cologuard Plus Collection Kit | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error